Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

412 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-12

Study Completion Date

2029-06-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

NCT00478426

Endometrial Adenocarcinoma Endometrial Endometrioid Adenocarcinoma Endometrial Serous Adenocarcinoma +5 more

COMPLETED PHASE2

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

NCT05522231

Advanced Renal Cell Carcinoma

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

NCT06317298

Renal Cell Carcinoma, Clear Cell, Somatic

RECRUITING NA

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

NCT01111461

Endometrial Cancer

COMPLETED PHASE2

Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma

NCT07156019

Neuroendocrine Carcinomas (NEC)

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized, open, positive-controlled, multicenter Phase III clinical study to compare the efficacy and safety of fruquintinib(HMPL-013) plus sintilimab(IBI308) versus chemotherapy in patients with advanced endometrial cancer who have progressed after first-line standard chemotherapy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Endometrial Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Patients will be treated with a planned dose of fruquintinib and sintilimab every three weeks until an IRC (independent review committee)-confirmed PD(disease progression) or meeting other discontinuation criteria.

Group Type EXPERIMENTAL

fruquintinib

Intervention Type DRUG

Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.

sintilimab

Intervention Type BIOLOGICAL

Sintilimab will be intravenously administrated on Day 1 every three weeks.

Control group

Patients will be treated with TPC (chemotherapy of treating physician's choice, paclitaxel or doxorubicin) every three or four weeks until IRC-confirmed PD or meeting other discontinuation criteria.

Group Type ACTIVE_COMPARATOR

paclitaxel

Intervention Type DRUG

175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.

doxorubicin

Intervention Type DRUG

60mg/m\^2 via IV infusion, on Day 1 every three weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fruquintinib

Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.

Intervention Type DRUG

sintilimab

Sintilimab will be intravenously administrated on Day 1 every three weeks.

Intervention Type BIOLOGICAL

paclitaxel

175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.

Intervention Type DRUG

doxorubicin

60mg/m\^2 via IV infusion, on Day 1 every three weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HMPL-013 IBI308

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Have fully understood and voluntarily signed the informed consent form
2. Age 18 to 75 years (inclusive) ; Body mass index (BMI) ≥ 18.5kg/m\^2;
3. Histologically or cytologically confirmed advanced or recurrent endometrial cancer with measurable lesions
4. Patients who previously failed first-line systemic platinum-based therapy
5. ECOG PS (Eastern Cooperative Oncology Group performance status score) 0 or 1;
6. Need to provide tumor samples for central lab testing of biomarkers such as MSI(microsatellite instability) status;
7. Non-MSI-H(non-microsatellite instability-high) by central lab or previous test result indicating pMMR(proficient mismatch repair);
8. Adequate function of the major organs;
9. Expected survival ≥ 12 weeks;
10. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days before randomization.

Exclusion Criteria

1. Endometrial carcinosarcoma or sarcoma;
2. Known MMR(mismatch repair)/MSI status with dMMR(deficient mismatch repair) or MSI-H(microsatellite instability-high);
3. Toxicities related to prior anticancer therapy did not recover to ≤CTCAE Grade 1, except alopecia and oxaliplatin-induced peripheral neurotoxicity ≤CTCAE Grade 2;
4. Received systemic anti-tumor therapy approved within 4 weeks before randomization;
5. Other malignancies within the past 5 years;
6. Previous or screening central nervous system (CNS) metastases;
7. Radical radiotherapy within 4 weeks before randomization
8. Previously received any anti-programmed cell death receptor-1 (PD-1) antibody, anti-PD-L1(programmed death ligand-1) antibody, anti-PD-L2(programmed death ligand-2) antibody, or anti cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody or any other antibody acting on T cell costimulation or checkpoint pathways (eg, OX40, CD137, etc) or small molecule vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors;
9. Symptomatic or treatment-requiring thyroid dysfunction at screening;
10. Use of immunosuppressive agents within 4 weeks before randomization
11. Presence of any active autoimmune disease requiring systemic treatment or history of autoimmune disease within the past 2 years;
12. Systemic immunostimulants within 4 weeks before randomization;
13. Administration of any live or live-attenuated vaccine within 4 weeks before randomization or planned during the study;
14. Major surgical procedures within 4 weeks before randomization;
15. Uncontrolled malignant pleural effusion, ascites or pericardial effusion;
16. Patients with current hypertension uncontrolled by medication;
17. Patients with any current disease or condition affecting drug absorption, or patients unable to take oral medications;
18. Receiving strong inducers of cytochrome P450 3A4 enzyme;
19. Patients with gastrointestinal diseases or unresected tumors with active bleeding, or other conditions that may cause gastrointestinal bleeding and perforation as judged by the investigator; or with gastrointestinal perforation or gastrointestinal fistula, which is not recovered after surgical treatment;
20. Active bleeding within 3 weeks before randomization, or melena, or bleeding from a tumor within 2 weeks before the first dose ;
21. Tumor invading major vascular structures and is judged by the investigator to be at greater risk of massive haemorrhage;
22. Patients who had arterial thrombosis or deep venous thrombosis within 6 months before randomization; or patients who had stroke events and/or transient ischemic attack within 12 months; patients who had thrombosis caused by implantable intravenous infusion pump or catheter, except patients who had stable thrombosis after conventional anticoagulant therapy;
23. Clinically significant cardiovascular disease;
24. Clinically significant electrolyte abnormalities as judged by the investigator;
25. Active infection or fever of unknown origin before randomization;
26. Patients with active pulmonary tuberculosis (TB) receiving anti-tuberculosis treatment or anti-tuberculosis treatment within 1 year before randomization;
27. Patients with previous and current history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired pulmonary function, which may interfere with the detection and management of suspected drug-related pulmonary toxicity; previous or current (non-infectious) pulmonary inflammation requiring steroid hormone therapy;
28. Positive human immunodeficiency virus (HIV) antibody screening;
29. Known history of clinically significant liver disease
30. Known hypersensitivity to any of the study drugs or any of their excipients, or previous history of serious hypersensitivity to any other monoclonal antibody;
31. Patients who have received other clinical drugs that have not been approved or marketed within 4 weeks before randomization;
32. Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
33. Patients who have received tissue/organ transplantation;
34. Patients with known psychiatric disorders or substance abuse disorders that could affect study compliance;
35. Patients who, in the opinion of the investigator, have other reasons that would make them inappropriate for this clinical study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiaohua Wu

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.